We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+31.61%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.19B
AUM Growth
+$204M
Cap. Flow
+$47.2M
Cap. Flow %
3.96%
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22.4M
2
FOLD
Amicus Therapeutics
FOLD
+$14.4M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$13.8M
4
BLUE
bluebird bio
BLUE
+$11.6M
5
RLYP
RELYPSA INC COM
RLYP
+$11.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
3
ARWR icon
Arrowhead Research
ARWR
+$18.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.7M
5
HCA icon
HCA Healthcare
HCA
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 79.53%
2 Miscellaneous 19.28%
3 Consumer Staples 1.08%
4 Financials 0.1%
5 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYH icon
151
Community Health Systems
CYH
$419M
– –
-2,569
Closed -$116K
ELV icon
152
Elevance Health
ELV
$90.6B
– –
-901
Closed -$108K
ENTA icon
153
Enanta Pharmaceuticals
ENTA
$358M
– –
-3,040
Closed -$120K
ICLR icon
154
Icon
ICLR
$13.3B
– –
-2,440
Closed -$140K
ITGR icon
155
Integer Holdings
ITGR
$4.29B
– –
-2,681
Closed -$104K
LGND icon
156
Ligand Pharmaceuticals
LGND
$5.52B
– –
-3,599
Closed -$105K
MCK icon
157
McKesson
MCK
$105B
– –
-527
Closed -$103K
MODV
158
DELISTED
ModivCare
MODV
– –
-2,532
Closed -$122K
PBYI icon
159
Puma Biotechnology
PBYI
$477M
– –
-11,000
Closed -$2.62M
VXRT
160
DELISTED
Vaxart
VXRT
– –
-23,036
Closed -$626K
CMRX
161
DELISTED
Chimerix, Inc.
CMRX
– –
-128,000
Closed -$3.54M
VIRX
162
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-1,905
Closed -$2.86M
VIRX
163
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-1,905
Closed -$2.86M
TRVN
164
DELISTED
Trevena, Inc.
TRVN
– –
-1,232
Closed -$4.94M
ABMD
165
DELISTED
Abiomed Inc
ABMD
– –
-25,000
Closed -$789K
AERI
166
DELISTED
Aerie Pharmaceuticals
AERI
– –
-1,121,951
Closed -$5.44M
MGLN
167
DELISTED
Magellan Health Services, Inc.
MGLN
– –
-2,189
Closed -$120K
HRC
168
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-2,657
Closed -$110K
NXTM
169
DELISTED
NxStage Medical Inc.
NXTM
– –
-20,000
Closed -$263K
AMSG
170
DELISTED
Amsurg Corp
AMSG
– –
-2,348
Closed -$118K
AEGR
171
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-366,754
Closed -$12.2M
PTX
172
CALL
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-2,500
Closed -$192K
PCYC
173
DELISTED
PHARMACYCLICS INC
PCYC
– –
-40,000
Closed -$4.7M
ASPX
174
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-100,000
Closed -$2.57M
GTIV
175
DELISTED
GENTIVA HEALTH SERVICES INC
GTIV
– –
-7,052
Closed -$118K
4 5 6
7
8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Perceptive Advisors deployed $47.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.

  • Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
  • Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
  • Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
  • Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
  • Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.

Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.